u~ The authors review the clinical and pathological features of 24 patients with gliosarcoma. The study revealed the following findings. Gliosarcoma occurs more frequently than is indicated in the literature, and in our series was present in 8% of all cases of glioblastoma multiforme. The presenting features are not significantly different from those of glioblastoma multiforme. The lesion often presents itself at surgery as a firm, well circumscribed mass within the temporal lobe, and at surgery it is commonly mistaken for a meningioma. There is an increased likelihood of metastasis compared to that of glioblastoma. The prognosis is no worse than that of glioblastoma, in spite of the addition of sarcomatous elements.
G
LIOSARCOMA is a brain tumor composed of neoplastic glial cells in association with spindle-celled sarcomatous elements. Since its original description by Stroebe, 4~ it has gained wide acceptance due to individual case reports 2,1.,29 and experimental studies) 4 In spite of this, there has been to our knowledge no comprehensive analysis of the clinical features of patients with these tumors, nor information as to their prognosis. During the past 18 years at the New York University-Bellevue Medical Center, we have seen 24 examples of this tumor. The present study constitutes a clinical and pathological survey of these 24 patients and reviews the previous literature.
Clinical Material
We examined the medical and pathological records of all patients having the diagnosis of gliosarcoma made by microscopic examination of either operative or autopsy material. This retrospective study covers the 18-year period from January, 1956, to December, 1974 . All the pathological material was obtained from the University and Bellevue Hospitals in New York City. Long-term data were obtained from outpatient clinic records and from the New York City Board of Health.
Summary of Cases

Incidence
All surgical pathological reports were reviewed at both institutions. In the past 18 years, of 1418 cases of brain neoplasm operated on at these hospitals, 457 were diagnosed as astrocytomas. Of this group, 308 were either markedly or moderately-to-markedly anaplastic, corresponding roughly to Grade III and IV astrocytomas. During the same period, 24 cases were diagnosed as gliosarcomas at these two institutions. Thus, based on the combined data from a large public and a large private hospital over a long period of time, gliosarcoma occurs with a frequency of approximately 2% compared with all brain tumors, 5% compared to all astrocytomas, and 8% compared to anaplastic astrocytomas.
Sex and Age
There were 14 men and 10 women in the series; this male predominance is also seen in patients with anaplastic astrocytomas. The patients ranged in age from 37 to 68 years, with an average age of 54 years. The majority of patients with these tumors were between 50 and 70 years old (Table 1) .
Location
Thirteen tumors were on the right and 11 on the left. There was a marked temporal lobe predominance (Table 2 ) with 10 of the tumors wholly within the temporal lobe and four partially so. Six tumors were in the parietal lobe, and four in the frontal lobe. This temporal lobe preponderance, which is not seen in anaplastic astrocytomas) ~ is reflected in the cases previously reported in the literature (Table 3) . We are aware of no factor that can explain this observation.
Symptoms and Signs
Signs and symptoms encountered in this and other series of gliosarcoma are presented in Table 3 . The most common initial symptoms with their percentage of incidence as the first indication of a brain tumor are given in Table 4 . The most common symptom on admission was weakness (60% of patients); next was headache (55%) ( Table 5 ). The headache was general in character in most patients and was localized to one side of the head in five patients, all of whom were subsequently found to have tumors on that side.
The neurological signs noted on examination were those typical of a brain tumor (Table 3) . Focal weakness was found in 83% of the 24 patients. A homonymous hemianopsia was detected in 54%, papilledema in 46%, and dysphasia in 29%. 
Laboratory Investigations
A lumbar puncture was carried out in 18 of 24 patients. The cerebrospinal fluid (CSF) protein ranged from 30 to 228 mg% and was abnormal (>45 rag%) in 78% of the patients. The average CSF protein value for this group of 18 patients was 107 mg%. Electroencephalography (EEG) was carried out in 13 of the 24 cases. In all 13, the EEG showed focal slowing in the area of the tumor. Brain scans performed in five of the 24 cases showed increased pickup over the area of the tumor. Cerebral angiography, carried out in 21 patients, showed an area of abnormal vascularity with early draining veins. In 19 cases, the angiograms were thought to be most consistent with a malignant brain tumor. In two cases, the angiographic picture was interpreted as a meningioma, with a part of the vascular supply arising from the external carotid artery. In no case was the diagnosis of gliosarcoma made before surgery. T r e a t m e n t Surgery. All patients in this series und e r w e n t surgery as the p r i m a r y t r e a t m e n t . (Fig. 1) . In three cases it was t h o u g h t at surgery t h a t the t u m o r r e m o v e d h a d been a m e n i n g i o m a ; in a fourth case the t u m o r was thought to be a sarcoma, and in a fifth, a m e t a s t a t i c nodule.
In 15 cases the t u m o r was located deep within the b r a i n and did not present on the surface. In one i n s t a n c e the t u m o r presented on the surface o f the t e m p o r a l lobe but was not a t t a c h e d to the meninges; in a n o t h e r case it was a d h e r e n t to the lower surface of the falx cerebri. In one p a t i e n t it was located deep within the t e m p o r a l l o b e but was t h o u g h t by the o p e r a t i n g s u r g e o n s to arise from the d u r a over the p e t r o u s ridge.
FIG. 2. Survival of patients with gliosarcoma after onset of symptoms (left) and after surgery (right).
Radiation Therapy. Radiation therapy was given in 18 of the 24 cases. The desired tumor dose was 5000 to 6000 rads, and this total dosage was given when patient survival allowed (13 of 18 cases).
Chemotherapy. Chemotherapy was used as an adjunct to radiation therapy in nine cases. Five patients were given mithramycin, two B C N U , one adriamycin, and one intracarotid amethopterin.
Survival
Survival data are available on 23 of the 24 patients (Fig. 2) . The average length of survival for all patients was 26 weeks after onset of symptoms and 21 weeks after surgery. In those patients who survived long enough to receive radiation therapy (that is, at least 5 weeks after surgery), the average survival was 37 weeks after the initial symptoms and 33 weeks after surgery. At the end of 6 months, there was a 75% survival rate; and at the end of 1 year, it was 19%. In the group of patients who received both radiation therapy and chemotherapy, the average survival rate was 39 weeks after onset of symptoms and 36 weeks after surgery. Because both treatment groups were biased by the selection of only those patients who survived at least 5 weeks postoperatively, we do not interpret the above survival data as necessarily indicating a beneficial effect from radiation therapy and/or chemotherapy on the survival of patients with gliosarcoma.
Pathological Findings
Surgical material was obtained from all 24 cases in this series. A diagnosis of gliosarcoma was made from the surgical specimen in 20 cases, and a diagnosis of anaplastic astrocytoma in four. In 19 cases in which a diagnosis of gliosarcoma had been made on examination of the surgical specimen, the surgical diagnosis was confirmed at autopsy. In one case in which a diagnosis of gliosarcoma had been made on examination of the surgical specimen, autopsy revealed no residual sarcomatous area, and the diagnosis of anaplastic astrocytoma was then made. In this case it is possible that the sarcomatous area, firmer in consistency than the surrounding gliomatous tissue, may have been removed in toto by the surgeon, leaving only gliomatous tissue within the brain.
In four cases the surgical specimen was diagnostic of an anaplastic astrocytoma, while examination of the whole brain at autopsy revealed areas of sarcomatous change that had not been seen on the surgical specimen. The intervals between surgery and autopsy in these four cases were 7, 8, 16, and 28 weeks (average 14.8 weeks). Whether this change from anaplastic astrocytoma to gliosarcoma was due to a sampling problem or to an actual induction of sarcomatous change in the vasculature during the period between examinations is impossible to determine from this data.
In this series of 24 patients, although autopsies were obtained in 11 instances, postmortem examination was limited to the brain in six instances. In the remaining five cases complete autopsy revealed no instances of tumor metastases on either gross or microscopic examination. In addition, examination of all charts revealed that in no instance was metastatic disease suspected either clinically or on the basis of laboratory examination prior to the patient's death.
Discussion
Since the original description by Stroebe in 1895, *~ there have been reports of approximately 60 cases of gliosarcoma. In our own data the incidence of 5% compared to all astrocytomas is somewhat higher than the estimate of 1.7% made by Wislowski" from a series of 700 gliomas and that of 2.3% made by Feigin, et al., 7 in a series from another institution. Had we compared the number of gliosarcomas to the number of gliomas rather than to the number of astrocytomas, our incidence figure would have been slightly closer to those previously reported. The reason for this discrepancy is not readily apparent.
The question of terminology has been a confusing one in the past. Stroebe '~ seems to have used the term "gliosarcoma" for a tumor composed of both gliomatous and sarcomatous elements, although Globus and Strauss 15 implied that Stroebe was using the term to refer only to the endothelial hyperplasia so commonly seen in anaplastic astrocytomas. Over the next 30 years the term gliosarcoma was used for the tumors we presently call anaplastic astrocytomas. Consequently, the term "gliosarcoma" lost the specific meaning it had originally. Since the work of Bailey and Cushing, 1 and Kernohan, et al.fl 2 all the generally used classifications of brain tumors have accepted the ectodermal origin of gliomas; 84 therefore we now feel these tumors might again be called "gliosarcomas." The more precise designation, "composite astrocytomasarcoma" is cumbersome, while the word "gliosarcoma," although inexact and possibly misleading, has been adopted by most recent authors on the subject? ~.8~,' 4 It should be recognized that this term cannot be applied to essentially the same process whereby a sarcoma develops as a consequence of the endothelial hyperplasia induced by a metastatic carcinoma? 6 The term "gliosarcoma" would be accurate but misleading if applied to a sarcoma developing in response to the presence of an oligodendroglioma.
The blood vessels of an astrocytoma tend to be abnormal, often thickened, fibrotic, hyalinized, and sometimes necrotic and thrombosed. 17, 39 We are concerned particularly with the hypertrophy and hyperplasia of endothelial cells and possibly other mural cell elements, which tend to be more severe the greater the degree of anaplasia of the astrocytoma. This hyperplastic reaction is common in the brain in response to almost any injurious process, and in fact a slight degree of such endothelial hyperplasia may be seen in low-grade gliomas; the response to the presence of malignant tumors, however, may be of far greater severity than that induced by these other processes. It is also far more severe than the vascular reactions in other organs under any circumstances.
In rare instances, the process goes beyond that of a hyperplastic reaction and assumes the properties of a neoplastic change. The degree to which the cells are atypical becomes greater and, more importantly, the tissues grow beyond the limits of the blood vessels from which they originated. These tissues assume the appearance of a spindle-cell fibrosarcoma (Fig. 3) and would be so considered on histological grounds without regard to the presence or absence of the astrocytomatous tissues. They tend to be composed of cells with relatively thick, elongated, moderately chromatic nuclei and an indistinctly outlined, eosinophilir cytoplasm; the cells vary appreciably in size, shape, and staining characteristics. They tend to be arranged in parallel rows that interweave, and collagen and reticulin fibers are demonstrated among them (Fig. 3) . Histological characteristics are very important in distinguishing sarcomatous tissues from astrocytomatous tissues, often called piloid astrocytomas or polar spongioblastomas, in which the cells may appear somewhat similar, but in which glial fibers, not connective tissue fibers, may be demonstrated with phosphotungstic acid hemotoxylin stains. These sarcomatous tissues infiltrate the adjacent astrocytomatous or normal tissues, at times quite widely, and in a few instances outgrow the astrocytomatous tissues and come to form the bulk of the tumor. It is possible that some of the apparently primary fibrosarcomas of the brain parenchyma may take origin in this fashion, with the astrocytomatous tissues forming so small a proportion of the tumor as to escape attention.
From the diagnostic point of view, the connective tissue reactions to leptomeningeal involvement by tumor, to tumor necrosis, and to some neuronal tumors, must be distinguished from the gliosarcomas under discussion. While connective tissue fibers are readily demonstrated in these circumstances by special stains, ordinary stains do not demonstrate spindle-cell sarcoma in these tissues. The criteria for diagnosis have been reviewed previously by one of the authors and will be mentioned here only briefly. The diagnosis of gliosarcoma should be made when a tumor contains an admixture of two distinctive neoplastic tissues. One is an anaplastic astrocytoma, as determined by all the usual histological criteria. The other tissue resembles a fibrosarcoma, and is composed of large cells with elongated or fusiform, moderately chromatic nuclei often arranged in parallel rows with deeply eosinophilic coarse fibers. These fibers resemble connective tissue fibers in that they can be stained tan by the phosphotungstic acid technique, blue by the azocarmine method, and deeply stained in Wilder's silver preparation for reticulin. The two tissues are intimately interwoven in many areas. Each tissue is histologically malignant, as evidenced by mitotic figures, high cellularity, and significant atypical features and variability. Zones of necrosis are present that involve both tissues.
In the anaplastic areas of the astrocytoma, the marked hyperplasia and hypertrophy of the cells of the vessel walls, characteristic of this tumor, are evident. In some vessels these changes are particularly marked and are associated with an appearance of atypical features, cellular variability, mitotic figures, and disorganization with occasional distorted, highly bizarre cells, an appearance that suggests that neoplastic transformation has occurred. In some areas, these cells extend outward from the wall to form masses of sarcomatous tissue. The sarcomatous infiltrating tissue often forms rounded nodules that encompass the strands of astrocytomatous tissue, as if the sarcomatous tissue had arisen from a structure located within the existing anaplastic astrocytoma.
A survey of the previous reports of gliosarcoma reveals that such cases can be divided into three groups. In the first group, the appearance of the astrocytoma and the sarcoma was probably coincidental, in the judgment of the authors. 18,45 Second are those in which the authors believe that there was a glial proliferation that continued to glioma, in response to the presence of a sarcoma? 9a6 The third and most common group is that in which the sarcoma appears to have arisen from endothelial hyperplasia within the anaplastic astrocytoma. 16,2~
It seems likely that cases such as those reported by Nichols and Wagner, 2~ in which there was an anaplastic astrocytoma in one occipital lobe and a sarcoma in the other, without any area of contact, can best be explained by the simultaneous appearance of two tumors. In the cases reported by Onofrio, el al.fl 8 and Mayo and Barronfl 5 there was a fibrous sarcoma of the leptomeninges that had been in contact with an astrocytoma beneath. These authors also conclude that their cases are most likely due to the chance occurrence of two lesions.
Other authors describe instances in which the sarcomatous element is primary and then elicits the growth of the gliomatous elements. Such an interpretation is most tenable in the cases reported by CourviUe and Edmondson, 4 and Chiasserini and Marchiafavafl where a sarcomatous change occurred in a meningioma that had invaded the skull and then penetrated the dura to enter the brain. The fact that the brain beneath contained an anaplastic astrocytoma is in accord with Rubinstein's suggestion that the glioma formation may in fact be secondary in some cases? 3 Review of the literature indicates that this is less common than the converse situation.
We believe that most gliosarcomas arise initially from anaplastic astrocytomas, by what begins as endothelial hyperplasia. This conclusion is the consensus of most authors. 8,~,",28,87,88,43 The previous case reports have stressed the marked endothelial hyperplasia that has occurred in the gliomatous portions of these neoplasms. In general, this endothelial hyperplasia will vary with the degree of malignancy of the tumor and the particular area under study. Both light and electron microscopic studies 29 have tended to confirm the fact that the sarcomatous portion of the gliosarcoma is but an extension of the endothelial hyperplasia so commonly seen in the anaplastic astrocytomas. A case has been reported in which a sarcoma was seen in association with a cerebral metastasis; 86 this finding supports the secondary nature of sarcoma formation within the brain, since the original neoplasm contained no sarcomatous elements.
The ability of the gliosarcoma to metastasize is much greater than that of other malignant brain tumors. Smith, et al.? 8 reported a series of seven cases of gliosarcoma that had metastasized outside the neuraxis, chiefly to the liver and the lung. These seven cases constituted nearly one third of the cases of metastasizing gliomas on file at the Armed Forces Institute of Pathology, a far greater number than could be accounted for by chance, since the gliosarcoma is 20 times less common than the glioma. This report on the greater frequency of metastasis in these tumors is reflected in the literature (Table 3) . Five other cases of gliosarcoma that metastasized postoperatively have been reported, s'5,Ta4,87 Metastasis did not occur in our series, but complete autopsy was permitted in only five of our 24 cases. It is of interest that in the l 1 cases of metastasis for which this information is available, the metastatic tissues contained both gliomatous and sarcomatous tissues in nine cases, and solely sarcomatous tissues in two cases. No metastatic lesion contained only gliomatous tissue.
Analysis of our cases reveals that from a clinical standpoint, the gliosarcoma does not differ significantly from the anaplastic astrocytoma or "glioblastoma multiforme" ( Table  6 ). As far as age, sex, clinical presentation, and survival are concerned, the two tumors are not substantially different. The only major differences are that the gliosarcoma is more likely to arise in the temporal lobe and that it is more circumscribed at surgery than the anaplastic astrocytomas. It is also more likely to metastasize than the anaplastic astrocytoma, but this is of no clinical import because it was invariably the primary cerebral neoplasm and not the metastasis that caused death in these patients.
We believe that over and above the clinical importance of the gliosarcoma is its contribution to our understanding of the neoplastic process. Experimental gliosarcomas can be produced indirectly by the resorptive carcinogens/6,41 or directly by the use of local carcinogens? ~ For example, Kroh 2~ found that gliosarcomas could be produced in 15% of all mice subjected to the intracerebral implantation of a methylcholanthrene pellet. However, the fact that in the experimental model the carcinogenic pellet can act simultaneously on every tissue with which it comes in contact raises a question as to the relevance of this particular model to the situation in humans.
Greene and Harvey, TM in a widely quoted paper, reported transplanting a "glioblastoma multiforme" that was originally from human donors and had been grown in the brain and eyes of guinea pigs. They were careful to transplant fragments mainly from the highly vascular peripheral aspects of the tumor instead of from the more necrotic central regions. Endothelial sarcomas developed in the subcutaneous transplants in hamsters inoculated with peripheral tumor tissue grown in the anterior chamber of the eye and in the brain. Successful transplantation and growth of sarcomas was also achieved in the mouse. These endothelial sarcomas were transplanted to many sites over a wide range of hosts and routinely metastasized.
In a series of experiments over the last 5 years, Folkman, et al., 1~ have put forward the concept that all tumors can grow beyond the diameter of several millimeters only if they are able to elicit the growth of new capillaries from the host. Although the precise mechanism by which solid tumors elicit new capillary growth is not clear, the authors present evidence that the information is transmitted from the tumor cell to the vascular endothelial cells by a diffusible factor, which they call "tumor angiogenesis factor." This is a protein molecule containing ribonucleic acid that has been found only in cultures of tumor cells and is mitogenic to the endothelium of capillaries and small vessels.
Within the last year, similar work done by Kelly, et al.,~ using an entirely in vitro system has extended this concept of tumor angiogenesis to nervous system tumors. It has been shown that both rat and human glial tumors in culture release a soluble material that will produce a significant increase in endothelial proliferation. Although this substance has not yet been isolated, we hypothesize that it is by means of such a soluble factor that the endothelial hyperplasia so commonly seen in anaplastic astrocytomas is produced. Excessive stimulation of the endothelial cells or lack of feedback inhibition would then cause a number of these stimulated endothelial cells to go on to become frankly neoplastic, leading to the formation of the gliosarcoma.
Summary
The clinical features of gliosarcoma have been studied in 24 patients, and the literature has been reviewed. Analysis of these cases has revealed the following:
1. Gliosarcoma is seen in about 8% of anaplastic astrocytomas 2. It is found more commonly in the temporal lobes 3. The presenting features are not significantly different from those of the anaplastic astrocytoma 4. The lesion often presents itself at surgery as a firm, well circumscribed area in an anaplastic astrocytoma 5. There is an increased likelihood of metastasis compared to that of anaplastic astrocytoma 6. The prognosis is no worse than that of the anaplastic astrocytoma in spite of the added sarcomatous elements 7. In most instances, the tumor is probably produced by excessive stimulation of endothelial cells by the surrounding anaplastic astrocytoma.
